2. Search Result
Search Result
Results for "

Veliparib

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10129
    Veliparib
    45+ Cited Publications

    ABT-888

    		 PARP Autophagy Cancer
    Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with Kis of 5.2 and 2.9 nM, respectively .
    Veliparib
  • HY-10130
    Veliparib dihydrochloride
    45+ Cited Publications

    ABT-888 dihydrochloride

    		 PARP Autophagy Cancer
    Veliparib (dihydrochloride) is a potent inhibitor of PARP1 and PARP2 with Kis of 5.2 nM and 2.9 nM in cell-free assays, respectively.
    Veliparib dihydrochloride
  • HY-105253
    PARP-2/1-IN-2

    		PARP Neurological Disease
    PARP-2/1-IN-2 (Compound 4a), the enantiomer of Veliparib (HY-10129), is a potent PARP inhibitor with Kis of 2 and 5 nM against PARP-2 and PARP-1, respectively. PARP-2/1-IN-2 has an EC50 of 3 nM in a cell based assay of PARP activity .
    PARP-2/1-IN-2
  • HY-10129R
    Veliparib (Standard)

    ABT-888 (Standard)

    		 Reference Standards PARP Autophagy Cancer
    Veliparib (Standard) is the analytical standard of Veliparib. This product is intended for research and analytical applications. Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with Kis of 5.2 and 2.9 nM, respectively .
    Veliparib (Standard)
  • HY-161517
    PARP1-IN-20

    		PARP Cancer
    PARP1-IN-20 (compound 19A10) is a potent inhibitor of PARP1, with the IC50 of 4.62 nM and has similar low PARP-Trapping effect compared with Veliparib (HY-10129), IC50 (MDA-MB-436) >100 μM .
    PARP1-IN-20
  • HY-10130R
    Veliparib dihydrochloride (Standard)

    ABT-888 dihydrochloride (Standard)

    		 PARP Reference Standards Autophagy Cancer
    Veliparib (dihydrochloride) (Standard) is the analytical standard of Veliparib (dihydrochloride) (HY-10130). This product is intended for research and analytical applications. Veliparib (dihydrochloride) is a potent inhibitor of PARP1 and PARP2 with Kis of 5.2 nM and 2.9 nM in cell-free assays, respectively.
    Veliparib dihydrochloride (Standard)
  • HY-130646
    iVeliparib-AP6

    		PROTACs PARP Cancer
    iVeliparib-AP6 is a proteolysis-targeting chimera (PROTAC) molecule designed based on Veliparib (HY-10129), which targets PARP1/2. The DC50s of iVeliparib-AP6 for inducing the degradation of PARP1 and PARP2 are 36 nM and 63 nM, respectively, and its IC50s are 69 nM and 21 nM, respectively. iVeliparib-AP6 contains a Veliparib-based PARP inhibitor warhead linked to a CRBN E3 ligase binder; it uses Thalidomide (HY-14658) as a ligand to recruit CRBN E3 ubiquitin ligase and exerts the PARP2 degradation mechanism .
    iVeliparib-AP6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: